Stock Taper
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotech developing treatments for neurodegenerative diseases, with lead candidate PrimeC for ALS and pipeline candidates for Parkinson’s and Alzheimer’s.

PrimeC, NeuroSense's oral fixed-dose combo of ciprofloxacin and celecoxib for ALS, has FDA and EMA Orphan Drug Designation and is preparing for Phase 3 after positive Phase 2b results.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
BCLI | $1.00 | COMPARE |
APRE | $0.85 | COMPARE |
ADIL | $6.57 | COMPARE |
ACXP | $1.44 | COMPARE |
CDIO | $2.07 | COMPARE |
ADXN | $3.69 | COMPARE |
CELZ | $1.10 | COMPARE |
HCWB | $2.53 | COMPARE |